Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Aprea Therapeutics, Inc. issued up to approximately 37.2 million shares of warrant to certain accredited investors for purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price.
- Security
- warrant
- Shares
- up to approximately 37.2 million shares
- Purchaser
- certain accredited investors
- Consideration
- purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price
Exact text from the filing
shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Aprea Therapeutics, Inc. issued Pre-Funded Warrant Shares of common stock to certain accredited investors for expected gross proceeds of the Private Placement are approximately $30 million.
- Security
- common stock
- Shares
- Pre-Funded Warrant Shares
- Purchaser
- certain accredited investors
- Consideration
- expected gross proceeds of the Private Placement are approximately $30 million
Exact text from the filing
occur on March 31, 2026, subject to satisfaction of customary closing conditions (the “ Closing Date ”). The expected gross proceeds of the Private Placement are approximately $30 million, before deducting the placement agent fees and estimated offering expenses payable by the Company. The Common Warrants will be exercisable immediately until December 31, 2029
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Gross proceeds of approximately $30 million (effective 2026-03-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- Gross proceeds of approximately $30 million
- Effective
- 2026-03-30
Exact text from the filing
On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to approximately 37.2 million shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.683 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”).
View on SEC.gov